Abstract 1005P
Background
Despite the availability of effective systemic therapies such as atezolizumab plus bevacizumab (A+B), the response rate remains unsatisfactory for patients with unresectable hepatocellular carcinoma with high tumor burden (uHTB-HCC). Our previous studies indicated that transarterial chemoembolization (TACE) combined with FOLFOX-based hepatic arterial infusion chemotherapy (HAIC) showed favorable results for HCC. This study aims to evaluate the efficacy and safety of A+B combined with TACE-HAIC for uHTB-HCC.
Methods
This retrospective study included uHTB-HCC (meeting at least one of the following criteria: beyond up-to-11, VP 3-4, extrahepatic metastases) pts who received TACE-HAIC followed by atezolizumab (1200mg IV) and bevacizumab (15mg/kg IV q4w) between March 2022 and December 2022. Efficacy was evaluated based on tumor response and survival rates, while safety was assessed by adverse events (AEs).
Results
Thirty-five uHTB-HCC pts received A+B combined with TACE-HAIC. Based on mRECIST criteria, the objective response rate (ORR) was 68.6%, with 8 (22.9%) pts achieved complete response, 16 (45.7%) partial response, 4 (11.4%) stable disease, and 7 (20.0%) progression disease. Additionally, 5 (14.3%) pts underwent curative hepatectomy after being converted to resectable HCC. The 1-year overall survival and progression-free survival rates were 94.3% and 71.4%, respectively. Of the 32 (91.4%) pts who experienced treatment-related adverse events (AEs), 13 (37.1%) had grade 3-4 AEs, but no treatment-related deaths occurred.
Table: 1005P
RECIST 1.1 (%) | mRECIST (%) | |
CR | 0 (0) | 8 (22.9) |
PR | 22 (62.9) | 16 (45.7) |
SD | 6 (17.1) | 4 (11.4) |
PD | 7 (20) | 7 (20.0) |
ORR | 22 (62.9) | 24 (68.6) |
Conclusions
The results suggested that A+B combined with TACE-HAIC was a promising treatment option for uHTB-HCC pts, given its excellent therapeutic efficacy and manageable adverse events.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
946P - Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Presenter: Shichun Lu
Session: Poster session 18
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18